Literature DB >> 7693753

Killing of rat glial cells by complement: deficiency of the rat analogue of CD59 is the cause of oligodendrocyte susceptibility to lysis.

S J Piddlesden1, B P Morgan.   

Abstract

In an effort to understand the mechanisms of complement-mediated injury of the myelin/oligodendrocyte complex in demyelinating disease, we have examined the lytic susceptibility of rat glial cells in culture. It is known that rat oligodendrocytes are extremely sensitive to the lytic action of autologous complement, whereas other cells in the same culture system, including type II astrocytes which derive from the same progenitor cell, are relatively insensitive. Here we demonstrate that the complement sensitivity of oligodendrocytes is associated with a lack of expression of a complement-regulatory protein, the rat homologue of human CD59, and that complement resistance can be restored by the incorporation of purified rat CD59 into the cell membrane. Furthermore, neutralisation of rat CD59 on complement-resistant astrocytes renders them susceptible to lysis. Immature oligodendrocytes were resistant to complement attack yet did not express CD59, suggesting that a complement-activating factor appears on the membrane during oligodendrocyte maturation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693753     DOI: 10.1016/0165-5728(93)90189-6

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  14 in total

Review 1.  Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodeling activities.

Authors:  Philippe Gasque; Jim W Neal; Sim K Singhrao; Eamon P McGreal; Yann D Dean; Beek Johan Van; B Paul Morgan
Journal:  Mol Neurobiol       Date:  2002-02       Impact factor: 5.590

2.  Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease.

Authors:  L B Yang; R Li; S Meri; J Rogers; Y Shen
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

3.  Molecular cloning of the rat analogue of human CD59: structural comparison with human CD59 and identification of a putative active site.

Authors:  N K Rushmere; R A Harrison; C W van den Berg; B P Morgan
Journal:  Biochem J       Date:  1994-12-01       Impact factor: 3.857

4.  Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis.

Authors:  S K Singhrao; J W Neal; N K Rushmere; B P Morgan; P Gasque
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

5.  p75 neurotrophin receptor expression on adult human oligodendrocytes: signaling without cell death in response to NGF.

Authors:  U Ladiwala; C Lachance; S J Simoneau; A Bhakar; P A Barker; J P Antel
Journal:  J Neurosci       Date:  1998-02-15       Impact factor: 6.167

6.  Expression and function of membrane regulators of complement on rat astrocytes in culture.

Authors:  C A Rogers; P Gasque; S J Piddlesden; N Okada; V M Holers; B P Morgan
Journal:  Immunology       Date:  1996-05       Impact factor: 7.397

7.  Complement regulatory protein expression by a human oligodendrocyte cell line: cytokine regulation and comparison with astrocytes.

Authors:  P Gasque; B P Morgan
Journal:  Immunology       Date:  1996-11       Impact factor: 7.397

8.  Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica.

Authors:  Lukmanee Tradtrantip; Xiaoming Yao; Tao Su; Alex J Smith; Alan S Verkman
Journal:  Acta Neuropathol       Date:  2017-05-31       Impact factor: 17.088

Review 9.  Complement in multiple sclerosis: its role in disease and potential as a biomarker.

Authors:  G Ingram; S Hakobyan; N P Robertson; B P Morgan
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

10.  Deficiency in complement C1q improves histological and functional locomotor outcome after spinal cord injury.

Authors:  Manuel D Galvan; Sabina Luchetti; Adrian M Burgos; Hal X Nguyen; Mitra J Hooshmand; Frank P T Hamers; Aileen J Anderson
Journal:  J Neurosci       Date:  2008-12-17       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.